HighTide Therapeutics places big IPO bet on “affluenza” drug
The company is pouring almost all its R&D budget into producing a metabolic drug to treat several conditions including diabetes Key Takeaways: With no products yet on the market, HighTide…
FAST NEWS: Structure Therapeutics Leaps in U.S. Trading Debut
The latest: Innovative drug developer Structure Therapeutics Inc. (GPCR.US) made its IPO trading debut last Friday, becoming the first major U.S. listing by a Chinese company this year.Looking up: The company…
MicroTech Medical Hong Kong IPO Greeted with Yawns
Diabetes device maker’s shares go largely unchanged in first four trading days despite attracting Invesco and two other mid-sized U.S. fund managers Key Takeaways: Diabetes device maker MicroTech Medical’s shares…
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
Akeso marks profit milestone with swift rights issue
9926.HK
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
-
Everest reaches new heights on growing drug sales
1952.HK
